Figure 2.
Independent radiological review committee (IRRC)-assessed progression-free survival at 6 months of patients treated with nivolumab (3 mg/kg every 2 weeks) who had not responded to ASCT and BV. CI, confidence interval. Reprinted from Younes et al11 with permission.
